NOVO B Stock Splits - Novo Nordisk A/S

Price: 442.95 DKK -0.75%

Have any thoughts about
Novo Nordisk A/S?

Write Note

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

Before the split, NOVO B traded at 681.5 per share. Afterward, the share price was about 673.7.

The adjusted shares began trading on Sep 13, 2023. This was NOVO B's 4th stock split, following the previous one in Jan 2, 2014.

Sep 13, 2023

2-for-1

Jan 2, 2014

5-for-1

Dec 3, 2007

2-for-1

Apr 4, 2001

5-for-1

Pre-Split Price

681.5 681.5

Post-Split Price

673.7

Adjust Price

Sep 13, 2023

2-for-1

Jan 2, 2014

5-for-1

Dec 3, 2007

2-for-1

Apr 4, 2001

5-for-1

Novo Nordisk A/S
Stock Splits History

Logarithmic

Sep 13, 2023

Split 2-for-1

Pre-Split Price

681.5 681.5

Post-Split Price

673.7

Adjust Price

Jan 2, 2014

Split 5-for-1

Pre-Split Price

65.5394 994

Post-Split Price

66.2317

Adjust Price

Dec 3, 2007

Split 2-for-1

Pre-Split Price

N/A

Post-Split Price

55.7641

Adjust Price

Apr 4, 2001

Split 5-for-1

Pre-Split Price

N/A

Post-Split Price

55.7641

Adjust Price

Global
Stock Splits Monitor

Forward Splits

Reverse Splits

Adjust Price

Date	Company		Split	Pre-Split Price	Post-Split Price
May 20, 2025		DeFi Development Corp NASDAQ:DFDV DFDV Valuation & Fundamental Analysis Stock Splits Performance Benchmark	7-for-1 x7	126.8001 18.1143 USD	178.3999 25.4857 USD
May 20, 2025	J	Janover Inc NASDAQ:JNVR JNVR Valuation & Fundamental Analysis Stock Splits Performance Benchmark	7-for-1 x7	887.6 126.8 USD	178.3999 25.4857 USD
May 20, 2025		Hangzhou Kelin Electric Co Ltd SSE:688611 688611 Valuation & Fundamental Analysis Stock Splits Performance Benchmark	1-for-1 x1	45.99 32.65 CNY	32.74 32.74 CNY
May 20, 2025	M	Magnum Goldcorp Inc OTC:MGIDF MGIDF Valuation & Fundamental Analysis Stock Splits Performance Benchmark	1-for-2 /2	0.02 0.02 USD	0.02 0.02 USD
May 20, 2025	S	Secuve Co Ltd KOSDAQ:131090 131090 Valuation & Fundamental Analysis Stock Splits Performance Benchmark	1-for-5 /5	4145 4145 KRW	4015 4015 KRW

Novo Nordisk A/S
Glance View

Economic Moat

Wide

Market Cap

2T DKK

Industry

Pharmaceuticals

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

View NOVO B Analysis

NOVO B Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Berkshire Hathaway Inc NYSE:BRK.A	Financial Services
US	Bank of America Corp NYSE:BAC	Banking
US	Mastercard Inc NYSE:MA	Technology
US	UnitedHealth Group Inc NYSE:UNH	Health Care
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	Palantir Technologies Inc NYSE:PLTR	Technology
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Walmart Inc NYSE:WMT	Retail
US	Verizon Communications Inc NYSE:VZ	Telecommunication
US	Chevron Corp NYSE:CVX	Energy

	Johnson & Johnson NYSE:JNJ	152.94 USD 0.22%
	Berkshire Hathaway Inc NYSE:BRK.A	754 505 USD -0.23%
	Bank of America Corp NYSE:BAC	43.2 USD -0.25%
	Mastercard Inc NYSE:MA	563.58 USD -1.15%
	UnitedHealth Group Inc NYSE:UNH	295.57 USD -0.37%
	Exxon Mobil Corp NYSE:XOM	103.03 USD 0.06%

	Franklin Covey Co NYSE:FC	22.87 USD -1.55%
	Mohawk Industries Inc NYSE:MHK	101.1 USD -1.19%
	Ardmore Shipping Corp NYSE:ASC	9.77 USD 1.88%
	ASGN Inc NYSE:ASGN	53.55 USD -1.22%
	Skyworks Solutions Inc NASDAQ:SWKS	69.39 USD -1.38%
	Weatherford International PLC NASDAQ:WFRD	45.5 USD -1.37%

	Johnson & Johnson NYSE:JNJ	152.94 USD 0.22%
	Bank of America Corp NYSE:BAC	43.2 USD -0.25%
	Mastercard Inc NYSE:MA	563.58 USD -1.15%
	Salesforce Inc NYSE:CRM	273.13 USD -3.63%
	Abbvie Inc NYSE:ABBV	183.26 USD 0.39%
	Home Depot Inc NYSE:HD	362.71 USD -0.93%

	Arista Networks Inc NYSE:ANET	91.2 USD -1.47%
	Visa Inc NYSE:V	353.54 USD -1.24%
	Texas Pacific Land Corp NYSE:TPL	1 272.41 USD -0.51%
	KLA Corp NASDAQ:KLAC	757.17 USD -1.35%
	Manhattan Associates Inc NASDAQ:MANH	185.23 USD -1.21%
	Monolithic Power Systems Inc NASDAQ:MPWR	662.18 USD -1.49%

Novo Nordisk A/S
CSE:NOVO B

NOVO B's latest stock split occurred on Sep 13, 2023

Novo Nordisk A/S
Stock Splits History

Global
Stock Splits Monitor

Novo Nordisk A/S
Glance View

Company

Help

Tools

Stocks

	ServiceNow Inc NYSE:NOW	1 004.37 USD -1.12%
	Spotify Technology SA NYSE:SPOT	653.82 USD 2.68%
	EOG Resources Inc NYSE:EOG	110.18 USD -0.55%
	Monster Beverage Corp NASDAQ:MNST	63.36 USD 0.78%
	Copart Inc NASDAQ:CPRT	53.67 USD -11.52%
	Applied Materials Inc NASDAQ:AMAT	157.51 USD -1.88%

52 Week Range	390 1 028
Price Target

Novo Nordisk A/S CSE:NOVO B

NOVO B's latest stock split occurred on Sep 13, 2023

Novo Nordisk A/S Stock Splits History

Global Stock Splits Monitor

Novo Nordisk A/S Glance View

Company

Help

Tools

Stocks

Novo Nordisk A/S
CSE:NOVO B

Novo Nordisk A/S
Stock Splits History

Global
Stock Splits Monitor

Novo Nordisk A/S
Glance View